Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Division of Endoscopy, Hokkaido University Hospital, Sapporo, Japan.
Endoscopy. 2020 Nov;52(11):967-975. doi: 10.1055/a-1185-9329. Epub 2020 Jun 24.
Prospectively collected long-term data of patients undergoing endoscopic resection for superficial esophageal squamous cell carcinoma (ESCC) are limited. The aim of this study was to determine the prospectively collected long-term outcomes of endoscopic resection for ESCC as a secondary analysis of the Japan Esophageal Cohort (JEC) study.
Patients who underwent endoscopic resection of intramucosal ESCC at 16 institutions between September 2005 and May 2010 were enrolled in the JEC study. All patients underwent endoscopic examination with iodine staining at 3 and 6 months after resection, and every 6 months thereafter. We investigated clinical courses after endoscopic resection, survival rates, and cumulative incidence of metachronous ESCC.
330 patients (mean age 67.0 years) with 396 lesions (mean size 20.4 mm) were included in the analysis. Lesions were diagnosed as high-grade intraepithelial neoplasia in 17.4 % and as squamous cell carcinoma in 82.6 % (limited to epithelium in 28.4 %, to lamina propria in 55.4 %, and to muscularis mucosa in 16.2 %). En bloc resection was achieved in 291 (73.5 %). The median follow-up period was 49.4 months. Local recurrences occurred in 13 patients (3.9 %) and were treated by endoscopic procedures. Lymph node metastasis occurred in two patients (0.6 %) after endoscopic resection. The 5-year overall, disease-specific, and metastasis-free survival rates were 95.1 %, 99.1 %, and 94.6 %, respectively. The 5-year cumulative incidence rate of metachronous ESCC was 25.7 %.
Our study demonstrated that endoscopic resection is an effective treatment for intramucosal ESCC, with favorable long-term outcomes.
目前可获得的接受内镜下切除治疗的早期食管鳞状细胞癌(ESCC)患者的长期数据有限。本研究旨在通过日本食管队列(JEC)研究的二次分析,确定内镜下切除治疗 ESCC 的前瞻性长期结果。
2005 年 9 月至 2010 年 5 月,16 家机构的 330 例接受内镜下黏膜内 ESCC 切除术的患者被纳入 JEC 研究。所有患者在切除后 3 个月和 6 个月以及此后每 6 个月接受内镜检查和碘染色。我们调查了内镜切除后的临床病程、生存率和异时性 ESCC 的累积发生率。
330 例患者(平均年龄 67.0 岁)共 396 处病变(平均大小 20.4mm)纳入分析。病变中 17.4%被诊断为高级别上皮内瘤变,82.6%为鳞状细胞癌(局限于上皮 28.4%,固有层 55.4%,黏膜肌层 16.2%)。291 例(73.5%)达到整块切除。中位随访时间为 49.4 个月。13 例(3.9%)患者发生局部复发,均经内镜治疗。2 例患者(0.6%)在内镜切除后发生淋巴结转移。5 年总生存率、疾病特异性生存率和无转移生存率分别为 95.1%、99.1%和 94.6%。5 年异时性 ESCC 的累积发生率为 25.7%。
我们的研究表明,内镜下切除是治疗黏膜内 ESCC 的有效方法,具有良好的长期疗效。